The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

APOA5  -  apolipoprotein A-V

Homo sapiens

Synonyms: APOA-V, APOAV, Apo-AV, ApoA-V, Apolipoprotein A-V, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of APOA5


Psychiatry related information on APOA5

  • This study investigates the association of AD with the APOA5 gene -1131T>C polymorphisms in samples of 106 patients with Alzheimer's disease (AD), 76 elderly healthy controls and 93 young healthy controls [6].

High impact information on APOA5


Chemical compound and disease context of APOA5


Biological context of APOA5


Anatomical context of APOA5


Associations of APOA5 with chemical compounds

  • In this study, we investigated the contribution of APOA5 to the liver X receptor (LXR) ligand-mediated effect on plasma triglyceride levels [1].
  • Dietary information was obtained from the Institute of Agricultural Economy. Results: In APOA5 Ser19Ser homozygotes (n=105), plasma cholesterol was relatively stable over the years (6.1+/-1.3 and 5.6+/-1.0 mmol/L in 1988 and 1996), but the decrease was much higher in Trp19 carriers (n=27; 6.5+/-1.6 vs. 5.1+/-1.1 mmol/L) [17].
  • Both rosiglitazone and the fish oil diet significantly increased Apoa5 mRNA, by about 70%, but tended to lower liver and plasma apoAV [13].
  • OBJECTIVE: Both the apolipoprotein A5 and C3 genes have repeatedly been shown to play an important role in determining plasma triglyceride concentrations in humans and mice [18].
  • SUBJECTS, MATERIALS AND METHODS: Plasma APOA5 concentration was measured by ELISA in 215 subjects with type 2 diabetes, who were taken from the Diabetes Atorvastatin Lipid-lowering Intervention (DALI) study, a 30-week randomised, double-blind, placebo-controlled study, and given atorvastatin 10 mg or 80 mg daily [19].

Physical interactions of APOA5

  • Using an oligonucleotide precipitation assay for USF from nuclear extracts, we demonstrate that phosphorylated USF1 fails to bind to the APOA5 promoter [3].
  • The presented data support the idea that the molecular mechanism of APOA5 function may include the enhancement of binding between lipoproteins and proteoglycans at the vascular wall and activation of proteoglycan-bound lipoprotein lipase [8].

Regulatory relationships of APOA5


Other interactions of APOA5

  • The major TG-raising alleles were defined by APOA5 W19 and APOC3 -482T [12].
  • However, there is no evidence that APOA5 S19W, -12,238T > C, APOA4 T347S and APCC3 -482C > T SNPs are major risk factors of CHD in French men [21].
  • Of the individual SNPs tested in the case-control panel, the strongest evidence of association was obtained with SNPs in APOA1 (P=0.001) and APOA5 (P=0.001) [22].
  • Treatment with atorvastatin decreased plasma APOA5, APOC3, APOE and triglycerides [19].
  • METHODS AND RESULTS: We sequenced APOA5 gene in 10 hypertriglyceridemic patients in whom mutations in LPL and APOC2 genes had been excluded [23].

Analytical, diagnostic and therapeutic context of APOA5


  1. The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c. Jakel, H., Nowak, M., Moitrot, E., Dehondt, H., Hum, D.W., Pennacchio, L.A., Fruchart-Najib, J., Fruchart, J.C. J. Biol. Chem. (2004) [Pubmed]
  2. A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Kao, J.T., Wen, H.C., Chien, K.L., Hsu, H.C., Lin, S.W. Hum. Mol. Genet. (2003) [Pubmed]
  3. Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor. Nowak, M., Helleboid-Chapman, A., Jakel, H., Martin, G., Duran-Sandoval, D., Staels, B., Rubin, E.M., Pennacchio, L.A., Taskinen, M.R., Fruchart-Najib, J., Fruchart, J.C. Mol. Cell. Biol. (2005) [Pubmed]
  4. Genetics of familial combined hyperlipidemia. Naukkarinen, J., Ehnholm, C., Peltonen, L. Curr. Opin. Lipidol. (2006) [Pubmed]
  5. APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study. Talmud, P.J., Martin, S., Taskinen, M.R., Frick, M.H., Nieminen, M.S., Kesäniemi, Y.A., Pasternack, A., Humphries, S.E., Syvänne, M. J. Lipid Res. (2004) [Pubmed]
  6. Apolipoprotein A-V gene polymorphism -1131T>C and Alzheimer's disease. Barbosa, F.A., de Labio, R.W., de Oliveira S Rigolin, V., Minett, T., Bertolucci, P.H., de Arruda Cardoso Smith, M., Pay??o, S.L. J. Alzheimers Dis. (2006) [Pubmed]
  7. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Pennacchio, L.A., Olivier, M., Hubacek, J.A., Cohen, J.C., Cox, D.R., Fruchart, J.C., Krauss, R.M., Rubin, E.M. Science (2001) [Pubmed]
  8. Give me A5 for lipoprotein hydrolysis! Merkel, M., Heeren, J. J. Clin. Invest. (2005) [Pubmed]
  9. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. Marçais, C., Verges, B., Charrière, S., Pruneta, V., Merlin, M., Billon, S., Perrot, L., Drai, J., Sassolas, A., Pennacchio, L.A., Fruchart-Najib, J., Fruchart, J.C., Durlach, V., Moulin, P. J. Clin. Invest. (2005) [Pubmed]
  10. Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins? Jakel, H., Nowak, M., Helleboid-Chapman, A., Fruchart-Najib, J., Fruchart, J.C. Ann. Med. (2006) [Pubmed]
  11. Apolipoprotein a5 and hypertriglyceridemia in prague hypertriglyceridemic rats. Kadlecová, M., Hojná, S., Bohuslavová, R., Hubácek, J.A., Zicha, J., Kunes, J. Physiological research / Academia Scientiarum Bohemoslovaca. (2006) [Pubmed]
  12. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Talmud, P.J., Hawe, E., Martin, S., Olivier, M., Miller, G.J., Rubin, E.M., Pennacchio, L.A., Humphries, S.E. Hum. Mol. Genet. (2002) [Pubmed]
  13. Apolipoprotein AV does not contribute to hypertriglyceridaemia or triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats. Dorfmeister, B., Brandlhofer, S., Schaap, F.G., Hermann, M., Fürnsinn, C., Hagerty, B.P., Stangl, H., Patsch, W., Strobl, W. Diabetologia (2006) [Pubmed]
  14. Apolipoprotein A-V: a potential modulator of plasma triglyceride levels in Turks. Hodoglugil, U., Tanyolaç, S., Williamson, D.W., Huang, Y., Mahley, R.W. J. Lipid Res. (2006) [Pubmed]
  15. Thyroid hormone regulates the hypotriglyceridemic gene APOA5. Prieur, X., Huby, T., Coste, H., Schaap, F.G., Chapman, M.J., Rodríguez, J.C. J. Biol. Chem. (2005) [Pubmed]
  16. APOA5 polymorphisms influence plasma triglycerides in young, healthy African Americans and whites of the CARDIA Study. Klos, K.L., Hamon, S., Clark, A.G., Boerwinkle, E., Liu, K., Sing, C.F. J. Lipid Res. (2005) [Pubmed]
  17. Polymorphisms in the APOA1/C3/A4/A5 gene cluster and cholesterol responsiveness to dietary change. Hubacek, J.A., Bohuslavova, R., Skodova, Z., Pitha, J., Bobkova, D., Poledne, R. Clin. Chem. Lab. Med. (2007) [Pubmed]
  18. Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice. Baroukh, N., Bauge, E., Akiyama, J., Chang, J., Afzal, V., Fruchart, J.C., Rubin, E.M., Fruchart-Najib, J., Pennacchio, L.A. Arterioscler. Thromb. Vasc. Biol. (2004) [Pubmed]
  19. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Dallinga-Thie, G.M., van Tol, A., Hattori, H., van Vark-van der Zee, L.C., Jansen, H., Sijbrands, E.J. Diabetologia (2006) [Pubmed]
  20. The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element. Prieur, X., Coste, H., Rodriguez, J.C. J. Biol. Chem. (2003) [Pubmed]
  21. Impact of APOA5/A4/C3 genetic polymorphisms on lipid variables and cardiovascular disease risk in French men. Dallongeville, J., Cottel, D., Montaye, M., Codron, V., Amouyel, P., Helbecque, N. International journal of cardiology. (2006) [Pubmed]
  22. Association of the APOLIPOPROTEIN A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia. Mar, R., Pajukanta, P., Allayee, H., Groenendijk, M., Dallinga-Thie, G., Krauss, R.M., Sinsheimer, J.S., Cantor, R.M., de Bruin, T.W., Lusis, A.J. Circ. Res. (2004) [Pubmed]
  23. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Oliva, C.P., Pisciotta, L., Li Volti, G., Sambataro, M.P., Cantafora, A., Bellocchio, A., Catapano, A., Tarugi, P., Bertolini, S., Calandra, S. Arterioscler. Thromb. Vasc. Biol. (2005) [Pubmed]
  24. Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges. Martin, S., Nicaud, V., Humphries, S.E., Talmud, P.J. Biochim. Biophys. Acta (2003) [Pubmed]
  25. Genetic variations of apolipoprotein A5 gene is associated with the risk of coronary artery disease among Chinese in Taiwan. Hsu, L.A., Ko, Y.L., Chang, C.J., Hu, C.F., Wu, S., Teng, M.S., Wang, C.L., Ho, W.J., Ko, Y.S., Hsu, T.S., Lee, Y.S. Atherosclerosis (2006) [Pubmed]
WikiGenes - Universities